logo.png
Cabaletta Bio to Present at Multiple August Investor Conferences
August 03, 2020 08:00 ET | Cabaletta Bio
PHILADELPHIA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
logo.png
Cabaletta Bio and Artisan Bio Announce Gene Editing Research and Collaboration Agreement to Develop Next-Generation CAAR T Cell Therapies
July 07, 2020 08:00 ET | Cabaletta Bio
PHILADELPHIA and DENVER, July 07, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell...
logo.png
Cabaletta Bio Announces Expansion of Sponsored Research Agreement with the University of Pennsylvania
May 28, 2020 08:00 ET | Cabaletta Bio
Collaboration deepens pipeline with CAAR design and optimization effort in three additional B cell-mediated autoimmune diseases PHILADELPHIA, May 28, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc....
logo.png
Cabaletta Bio to Present at Jefferies Virtual Healthcare Conference
May 27, 2020 08:00 ET | Cabaletta Bio
PHILADELPHIA, May 27, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
logo.png
Cabaletta Bio Announces Presentation of Data Supporting MuSK-CAART Development for the Treatment of the MuSK form of Myasthenia Gravis at the AAN 2020 Science Highlights Virtual Platform
May 18, 2020 16:30 ET | Cabaletta Bio
In vivo preclinical data show that Chimeric AutoAntibody Receptor (CAAR) T cells were able to specifically recognize and eliminate anti-MuSK antibody-expressing B cells while sparing control B cells ...
logo.png
Cabaletta Bio Reports First Quarter 2020 Financial Results and Provides Business Update
May 12, 2020 07:00 ET | Cabaletta Bio
PHILADELPHIA, May 12, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
logo.png
Cabaletta Bio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
March 30, 2020 07:00 ET | Cabaletta Bio
DSG3-CAART IND clearance received in October 2019 and Orphan Drug Designation granted by the FDA for the treatment of pemphigus vulgaris (PV) in January 2020; anticipated delay in reporting the acute...
logo.png
Cabaletta Bio to Present at the Cowen and Company 40th Annual Health Care Conference
February 20, 2020 08:00 ET | Cabaletta Bio
PHILADELPHIA, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
logo.png
FDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus Vulgaris
January 29, 2020 08:00 ET | Cabaletta Bio
PHILADELPHIA, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
logo.png
Cabaletta Bio to Present at the Evercore ISI 2nd Annual HealthCONx Conference
November 26, 2019 08:00 ET | Cabaletta Bio
PHILADELPHIA, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...